Category Archives: Immunology

Immunology

Clinical Immunology | Meso Scale Discovery

MSDs wide range of assay development materials and kits provide superior solutions for each stage of development in clinical and pre-clinical applications as compared to traditional methods. MSD assay sensitivity can be up to 1000-fold better than ELISA with a large linear range of 3-4 logs. MSDs electrochemiluminescence detection technology reduces background signals due to the stimulation mechanism (electricity) being decoupled from the signal (light). MSD assay formats minimize both matrix effects and free drug interference, improving both workflow and performance. MSD offers assays and reagents to enhance the performance of many clinical immunology applications, including:

Immunogenicity testing is a crucial part of biopharmaceutical development. More stringent recommendations regarding immunogenicity assay performance necessitates the development of more robust and tolerant assays. MSD assays are capable of identifying low affinity antibodies during initial screens, and have a large linear range that reduces the number of required dilutions. Assays can be built for many drug types using MSD technology, including antibodies, humanized antibodies, proteins, and peptides with reagents designed to provide a variety of flexible assay formats and facilitate rapid assay development.

Drug interference in immunogenicity assays from free drug in patient samples can cause false negatives and suppressed signal. The improved sensitivity of the MSD platform produces higher signal and lower backgrounds, leading to greater signal to background ratios, and detection of low levels of drug-anti drug antibody complexes. Improved assay sensitivity allows for larger sample dilution, further reducing drug interference.

The MSD technology platform easily facilitates the development of assays for neutralizing antibodies. These assays are a key step in the development and characterization of a biological therapeutic agent, as part of the screening process for immune responses to protein and antibody drugs. The versatility of MSD assay development reagents affords the choice of several types of neutralization assays, including a receptor binding/blocking assay format and a whole cell-based neutralization assay.

Pharmacokinetics is the study of the metabolism and action of drugs in the body, with emphasis on time course studies of adsorption, distribution, period of action, and excretion. Pharmacokinetics assays can easily be implemented on the robust MSD platform using our flexible assay development reagents.

The study of pharmacodynamics examines drug mechanisms of action, as well as their exerted biochemical and physiological effects. These effects can be generated through drug interaction with specific cellular proteins, and secreted proteins such as cytokines.

Streptavidin Gold Plates are designed to be the gold standard for assay performance, consistency, and convenience in immunogenicity testing, pharmacokinetic/pharmacodynamic studies, and assay development.

Read the original:
Clinical Immunology | Meso Scale Discovery

Immunology

Immunology Market Trends, Size, Share & Global Outlook 2026

Existing market players operating in the global immunology market are focusing on constant innovations and up-gradation of their product portfolio with new and efficient product offerings for better treatment outcomes for the patients. One of the primary reasons for the growth of the global market is the increasing incidence of immunological and autoimmune diseases. Rise in awareness regarding immunological diseases in both developing and developed nations, and the higher prevalence of immunological disorders due to environmental factors, thus propelling the of the global immunology market growth. This, coupled with, increasing investments by major players in research and development activities are also boosting the growth of the market globally.

Get comprehensive study about this report by, request a free sample copy

The change in the immunology market share is also primarily driven by a greater focus towards the R&D initiatives due to recent regulatory approvals, increasing trends of patent expiry and the subsequent emergence of comparatively cheaper biosimilars. Some of the other factors which are also contributing to the growth of the market are the increase in the efficiency of the immunology drugs leading to better patient outcomes and improved quality of life.

The introduction of new and sophisticated targeted therapies such as TREMFYA by Janssen Global Services, LLC (Johnson & Johnson) and Cosentyx by Novartis AG is expected to drive the growth of the immunology market in developed as well as emerging countries, during the forecast period 2019-2026.

"Increasing adoption of monoclonal antibody (mAb), combined with the increasing prevalence of immunological diseases is driving the growth of the global market "

Increasing adoption and demand for monoclonal antibody (mAb), which is the drug class of a number of immunology drugs and has a number of associated advantages such as its status as a high specific therapy, is one of the most prominent driving factors for the growth of the global immunology industry in 2018. Increasing R&D initiatives in the monoclonal antibody segment and a large number of drugs under the segment is also driving the growth in the monoclonal antibody (mAb) segment.

The immunosuppressant segment is estimated to grow at a faster CAGR during the forecast period. This is attributed to the anticipated increase in the revenue under this drug class, with the interleukin inhibitors becoming more prominent in the immunology market trend. Currently, there is increasing adoption of the immunosuppressants in the markets in the developing nations due to its higher achievement in terms of the efficient treatment leading to improved patient outcomes, and this is expected to contribute to the growth of the market at higher CAGRs during the forecast period.

To get details on market share, speak to analyst

Based on the drug class, the global immunology market segments include monoclonal antibody (mAb), fusion proteins, immunosuppressants, polyclonal antibody (pAb), and others. Monoclonal antibody (mAb) segment is estimated to have the largest market share among the drug class types.

The targeted therapy segment accounted for a market share of 64.5% in 2018 and is expected to rise during the forecast period. Based on disease indication, the global market segments include rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, inflammatory bowel disease, prophylaxis of organ rejection, and others. Based on the distribution channel, the global immunology industry segments include hospital pharmacies, retail pharmacies, online pharmacies, and others.

"Growing Prevalence and Awareness of Autoimmune and Immunological Disorders and Increasing Adoption of Immunology Drugs Expected to Result in The Highest CAGR in the Asia Pacific"

North America generated a revenue of US$ 41,622.5 Mn in 2018 and is anticipated to account for a dominant share in the global market during the forecast period. The immunology market growth witnessed in the region is likely to be driven by the increasing adoption of advanced immunology drugs and rising prevalence of autoimmune and immunological disorders.

This is especially applicable in instances where there is a steady escalation of the symptoms and the disease progresses due to lack of efficient treatment. In developed countries, the adoption of advanced immunology drugs such as immunosuppressants is increasing along with the existing drug classes of monoclonal antibody (mAb) and polyclonal antibody (pAb) amongst others.

North America Immunology Market, 2018

To get geographical overview of this market, request a free sample copy

Europe is estimated to be the second most dominant market after North America due to substantial R&D initiatives and adoption of advanced immunology drugs. Whereas, in emerging countries such as India and China, the rise in awareness of autoimmune and immunological disorders is fueling growth in the immunology market during the forecast period.

In countries like China and India, there is an existing conflict with the high prices attached to some of the immunology drugs. However, in countries like Japan, there is increased adoption and expenditure towards advanced immunology drugs. The Latin America and Middle East & Africa market is also estimated to have future growth potential in global immunology market growth.

"AbbVie Inc., Johnson & Johnson, and Roche dominated the global immunology market in 2018 "

AbbVie Inc., emerged as the leading player with the highest market share in 2018, as the company has the patent rights to HUMIRA (adalimumab), the worlds best-selling drug. The drug accounts for the highest revenue shares in the immunology segment and is approved for a number of disease indications including rheumatoid arthritis and psoriatic arthritis. In addition, other market players are also getting product approvals such as TREMFYA by Janssen Global Services, LLC (Johnson & Johnson) and Cosentyx by Novartis AG. Other players operating in the Immunology market are Janssen Global Services, LLC (Johnson & Johnson), F. Hoffmann-La Roche Ltd, Amgen Inc., Pfizer Inc., Novartis AG, Astellas, Bristol-Myers Squibb Company, Merck Sharp & Dohme Corp., UCB SA, and ALLERGAN.

The increasing prevalence of a number of autoimmune and immunological disorders in the general population is one of the key factors boosting the global immunology market revenue. The increasing R&D initiatives in the immunology industry and the recent regulatory approvals are also positively contributing to the growth of the market. The introduction of new products in the market, along with an increasing number of patients undergoing treatment for immunological diseases globally is projected to further augment the demand for immunology drugs during the forecast period.

The report provides qualitative and quantitative insights on the immunology industry trends and detailed analysis of immunology market size and growth rate for all possible segments in the market. The market segments include drug class, disease indication, distribution channel, and geography.

To get information on various segments, share your queries with us

On the basis of the drug class, the global market segments include monoclonal antibody (mAb), fusion proteins, immunosuppressants, polyclonal antibody (pAb) and others. On the basis of disease indication, the market is categorized into rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, inflammatory bowel disease, prophylaxis of organ rejection and others. On the basis of the distribution channel, the immunology industry is categorized into hospital pharmacies, retail pharmacies, online pharmacies, and others.

Along with this, the report analysis includes market dynamics and competitive landscape. Various key insights provided in the report are the prevalence of autoimmune and immunological disorders by key countries, regulatory scenario by key regions, key industry developments, overview of regulatory scenario by key countries, an overview of current advances in R&D for immunology.

ATTRIBUTE

DETAILS

By Drug Class

By Disease Indication

By Distribution Channel

By Geography

Read the original:
Immunology Market Trends, Size, Share & Global Outlook 2026

Immunology

Cuba and Thailand joint venture to manufacture cancer drugs – OnCubaNews

A Cuba and Thailand joint venture will soon start manufacturing cancer drugs, the Cuban media reported this Friday.

The enterprise is formed by the Thai pharmaceutical company Siam Bioscience (SBS) and the Cuban medicine industry and its operations will be initiated in the Association of South East Asian Nations (ASEAN), according to the official newspaper Granma, which quoted a tweet from Eduardo Ojito, director of Cubas Center for Molecular Immunology (CIM).

The publication affirms that the company emerged in 2017 to produce world-class drugs for complicated diseases, whereby the Thai SBS and the Cuban CIM agreed to jointly develop monoclonal antibodies to treat cancer and autoimmune diseases.

Songpon Deechongkit, general director of Siam Bioscience Group, to which SBS belongs, assured the Bangkok Post that by 2022 the enterprise plans to produce and sell three new drugs for cancer, kidney failure and autoimmune diseases, both in Thailand and abroad.

For his part, Agustn Lage Dvila, general director of CIM, told the publication itself that the agreement will help SBS produce other medicines when its patent expires, through the skills created in it.

Dos nuevos medicamentos para el cncer dan buenos resultados

The Thai pharmaceutical giant, according to the source, has as its main objective to reduce the costs of medicines with respect to imported products and seeks to reduce dependence on active ingredients and foreign components.

SBS has previously developed medications such as erythropoietin for patients with chronic renal failure and filgrastim for cancer patients receiving chemotherapy. Its operations have crossed Thailands borders to include ASEAN countries.

Established in 2009, Siam Bioscience has the mission of supporting and enhancing the countrys medical system and improving Thais quality of life, an objective that will now be extended to other ASEAN countries, which also include Indonesia, Malaysia Singapore and the Philippines.

See the original post:
Cuba and Thailand joint venture to manufacture cancer drugs - OnCubaNews

Immunology

THE REAL POLLEN COUNT: Grass season spreading to the coast – Health24

Amid the highest recorded pollen counts in history, Health24 will be bringing you exclusive pollen count updates courtesy of the UCT Lung Institute's Allergy and Immunology Unit.

Here are the major city updates for 20 February:

Cape Town (Western Cape)

Low grass counts were detected during this sampling week. Tree levels were low and included white stinkwood and pine. Weed levels were also low and the types identified were the daisy family, goosefoot and Erica. Moulds were low.

Count: 2 (very low) [Last week: 0 (very low)]

Johannesburg (Gauteng)

Grass counts were moderate throughout this sampling week. Very few tree pollens were in the air, with only a few grains of cypress and eucalyptus. Weeds were also low, with predominantly daisy detectable. Fungal spores were low.

Count: 18 (moderate) [Last week: 11 (moderate)]

Pretoria (Gauteng)

Overall counts were in the high range with grass pollen high to very high on most days of the sampling week. Tree pollen was minimal with only cypress, mulberry and eucalyptus detected.

Weed pollen, in the form of daisy was only detectable on two days. Fungal spores at the upper end of the low range, with aspergillosis and Cladosporium dominant.

Count: 35 (high)

Kimberley (Northern Cape)

Count: 12 (moderate) [Last week: 33 (high)]

Durban (KZN)

Grass levels were high at this sampling site. Tree loads increased, and were dominated by birch, with eucalyptus and white stinkwood also recorded. Weed levels were low, including ragweed.

Count: 45 (high) [Last week: 24 (high)]

Port Elizabeth

Grass levels were low. Tree were low and included Casuarina, Morella (waxberry)and yellowwood.

Weeds were low and the types detected were protea, the daisy family and Caryophyllaceae (the carnation family). Moulds were low, but increased after rain.

Count: 5 (low) [Last week: 1 (very low)]

Bloemfontein

Count: 97 (very high) [Last week: 114 (very high)]

See the full report HERE.

Reference ranges:

Overall, Trees, Grasses and Weeds all use the same values (grains per cubic metres of air).

Overall count is the daily average of pollen grains per cubic metres of air (trees plus grasses plus weeds)

In partnership with the UCT Lung Institute's Allergy and Immunology Unit.

As the pollen problem worsens, precise and expanded monitoring becomes even more essential. And here's how you can help.

Image: iStock

Read more:
THE REAL POLLEN COUNT: Grass season spreading to the coast - Health24

Immunology

Should an FDA warning affect your use of hand sanitizer? – WTOP

The FDA told the maker of Purell it could not claim that the product prevents viral illnesses, raising new questions about hand sanitizer use.

The Food and Drug Administration told the maker of Purell last month that it could not claim its product prevents the flu and other viral illnesses, raising new questions about hand sanitizer use.

In a letter to GOJO Industries, the FDA said it is currently not aware of any adequate and well-controlled studies demonstrating that killing or decreasing the number of bacteria or viruses on the skin by a certain magnitude produces a corresponding clinical reduction in infection or disease caused by such bacteria or virus.

Though the company may be limited in the claims it can make, hand sanitizers that have at least 60% alcohol content are still believed to be an important line of defense against getting sick, according to Dr. Julie Fischer, an associate research professor of microbiology and immunology at Georgetown University.

The correct use of hand sanitizer involves applying enough of it and rubbing your hands for 15 seconds, because the rubbing together actually helps destroy and remove those organisms as well, Fischer said.

Still, its preferred that you use soap and water and wash your hands correctly if you have time, she said, which means rubbing hands together for at least 20 seconds while washing.

Meanwhile, in an apparent vote of confidence for hand sanitizers, the FBI has ordered $40,000 of hand sanitizer and face masks in case the coronavirus becomes a pandemic in the United States, according to the acquisition document obtained by CNBC.

Like WTOP on Facebook and follow @WTOP on Twitter to engage in conversation about this article and others.

Get breaking news and daily headlines delivered to your email inbox by signing up here.

2020 WTOP. All Rights Reserved. This website is not intended for users located within the European Economic Area.

Read more here:
Should an FDA warning affect your use of hand sanitizer? - WTOP

Immunology

COVID-19: Why you should call the coronavirus by its official name – ABC10.com KXTV

SACRAMENTO, Calif. The outbreak of a new coronavirus, first detected in Wuhan City, China, now has an official name.

In comments to the media on Tuesday, Feb. 11, World Health Organization (WHO) General Director Tedros Adhanom Ghebreyesus announced a name for coronavirus: COVID-19.

"Having a name matters to prevent the use of other names that can be inaccurate or stigmatizing," he said during his remarks. "It also gives us a standard format to use for any future coronavirus outbreaks."

COVID-19 stands for coronavirus disease 2019.

Coronaviruses are a large family of viruses that are common in many different species of animals, including camels, cattle, cats and bats, according to the Centers for Disease Control and Prevention (CDC). The center says it's rare for animal coronavirus to infect people and then spread between people such as with MERS-CoV, SARS-CoV, and now with this new virus named SARS-CoV-2, which causes COVID-19.

WHO, the World Organisation for Animal Health and the Food and Agriculture Organization of the United Nations developed the name based on best practices, according to health officials. The disease was previously referred to as 2019-nCoV, shorthand for novel (new) coronavirus found in 2019.

"We had to find a name that did not refer to a geographical location, an animal, an individual or group of people, and which is also pronounceable and related to the disease," the director general said.

Tracey Goldstein, professor in the UC Davis Department of Pathology, Immunology and Microbiology, said it's important to have an official name for the virus to curb misinformation.

"People may call a virus or disease by an incorrect name based on species or locations," Goldstein said. "If people think a virus comes from a particular location they may treat people from that area inappropriately."

As of Wednesday, Feb. 19, there are 15 confirmed cases of COVID-19 in the United States, according to the CDC. Health officials confirmed thefirst case of coronavirus in Napa Countyon Tuesday after a local hospital took in a patient from Travis Air Force Base after they were flown in from Japan.

Globally, there are 75,204 confirmed cases of COVID-19, according to WHO.

RELATED:

FOR NEWS IN YOUR COMMUNITY,DOWNLOAD THE ABC10 APP:

Stay In the Know!Sign up now for ABC10'sDaily Blend Newsletter

WATCH ALSO:5 people quarantined at Travis Air Force Base showing coronavirus symptoms, CDC says

Go here to read the rest:
COVID-19: Why you should call the coronavirus by its official name - ABC10.com KXTV

Immunology

Neurology Professor from Harvard Medical School Wins Barancik Prize for Innovation in MS Research for Work Resulting in New Tools and Treatments to…

MEDIA CONTACT

Available for logged-in reporters only

Newswise Dr. Francisco J. Quintana, PhD, Professor of Neurology at Ann Romney Center for Neurologic Diseases at Brigham and Womens Hospital, Harvard Medical School, is the winner of the National Multiple Sclerosis Societys Barancik Prize for Innovation in MS Research.

While the genetic origins of MS are becoming better understood, its less known how environmental factorssuch as pollutants, diet and intestinal bacteriamight contribute to MS and its progression. It is also not yet known how risk factors influence the immune system to attack the central nervous system. To address these questions, Dr. Quintana uses cutting-edge technologies to study the regulation of immune responses and inflammation in MS, molecular changes that trigger MS and environmental factors that influence disease activity.

Through a series of high-impact publications, Dr. Quintanas work has contributed new tools to further the work of the MS research community. His research has led to potential drugs for treating progressive MS, and has contributed to the development of a designer treatment called nanoparticles to control autoimmune activity. He recently developed anti-inflammatory synthetic engineered probiotics as a novel approach to MS therapy, and his team is currently licensing these probiotics to a new biotech for their clinical testing.

I recently completed what is so far the largest single-cell analysis of central nervous system cells in MS and EAE models Since this work generated one of the largest datasets currently available, it provides a unique resource for the study of the CNS in health and disease, Dr. Quintana said. Thus, we expect these datasets and novel methods to have a deep impact on MS research.

As for future research plans, Dr. Quintana will serve as the lead researcher on an international collaboration to develop a pipeline to identify the origins of progressive MS and new or repurposed drugs to treat it. His long-term goal is to identify mechanisms of disease pathogenesis and develop therapies for progressive MS.

Dr. Quintana will receive the Barancik Prize and deliver the Prize lecture at the ACTRIMS Forum. ACTRIMS Forum brings together more than 1,200 researchers and clinicians annually to share developments in the rapidly changing field of MS. The 2020 Forum will be held Feb. 27-29, 2020, in West Palm Beach, Florida. Themed Networks in MS, this CME-accredited meeting stands apart from many traditional medical meetings by offering a single track of scientific and clinical presentations in an interactive environment.More information about ACTRIMS Forum appears on the events website. Follow the event at #ACTRIMS.

Dr. Quintana earned a diploma in biology from the University of Buenos Aires and a Ph.D. in immunology from the Weizmann Institute of Science in Rehovot, Israel. He completed his postdoctoral training with a focus on neuroimmunology at the Weizmann Institute and at BWH. Among his many awards are Young Investigator Awards in Ireland and Italy, a Pathway to Independence Award from NIAID/NIH, and the National Multiple Sclerosis Societys 2014 Harry Weaver Research Scholar Award and 2017 Milestones in MS Research Award. The recipient of the 2016 Young Mentor Award from Harvard Medical School, he has trained more than 30 graduate students and postdoctoral fellows, and participates in several programs focused on training scientists from underrepresented minorities. He directs the Autoimmunity post-graduate course at Harvard Medical School, and the Seminars in Immunology post-graduate course at the University of Sao Paulo, Brazil.

The Barancik Prize seeks to recognize and encourage exceptional innovation and originality in scientific research relevant to multiple sclerosis, with emphasis on impact and potential of the research to lead to pathways for the treatment and cure for MS, and scientific accomplishments that merit recognition as a future leader in MS research. The international prize is made possible by the generosity of the Charles and Margery Barancik Foundation, and is administered through the National Multiple Sclerosis Society.

Read about the Barancik Prize and previous recipients

About ACTRIMS Founded in 1995, Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) is a community of leaders from the United States and Canada who are dedicated to the treatment and research in MS and other demyelinating diseases. ACTRIMS focuses on knowledge dissemination, education and collaboration among disciplines. ACTRIMS also provides a Forum for experienced and newer clinicians and researchers to exchange information, debate current issues and discuss advances related to basic research and clinical issues.

View original post here:
Neurology Professor from Harvard Medical School Wins Barancik Prize for Innovation in MS Research for Work Resulting in New Tools and Treatments to...

Immunology

The Effect of CoQ10 Supplementation on Quality of Life in Women with B | PRBM – Dove Medical Press

Seyed Ahmad Hosseini,1 Nazanin Zahrooni,2 Ahmad Ahmadzadeh,3 Kambiz Ahmadiangali,4 Mohammad-Ali Assarehzadegan5

1Nutrition and Metabolic Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran; 2Department of Nutrition, Faculty of Paramedicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran; 3Thalassemia and Hemoglobinopathy Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran; 4Biostatistics Division, Health School, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran; 5Immunology Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Science, Tehran, Iran

Correspondence: Nazanin ZahrooniDepartment of Nutrition, Faculty of Paramedicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran Tel +98 61 3336 7543Fax +98-6133720299Email nzahroonii@gmail.com

Background: Survival rates among breast cancer patients and the number of patients living with treatment side effects have improved, leading to increased focus on quality of life (QOL). The objective of this study was to determine the efficacy of CoQ10 on QOL scores among breast cancer patients in Iranian undergoing tamoxifen therapy.Methods: Thirty breast cancer patients were randomized into two groups. The first group received 100 mg CoQ10, and the second group took fplacebo once a day for 8 weeks. QOL was evaluated by a standard QOL questionnaire and a specific questionnaire on QOL of breast cancer patients at baseline and the end of the study. Also, physical activity of patients was assessed with the IPAQ questionnaire and dietary intake determined by a 3-day dietary record.Results: The data of 30 subjects were analyzed. According to QOL C30 data, CoQ10 led to a significant increase in physical functioning (P=0.029), emotional functioning (P=0.031), and cognitive functioning (P=0.023) compared to placebo. Symptom scales revealed a notable reduction in appetite loss in the first group (P=0.01). Global health status showed no significant changes in either study arm. On the QOL BR23, progress in functions and decline in symptoms were not statistically significant. Arm symptoms showed significant reduction (P=0.022) in patients that received placebo.Conclusion: This trial indicates that CoQ10 supplementation has effects in ameliorating some dimensions of QOL in breast cancer patients. To generalize the results, larger and longer intervention studies are needed.Clinical Trial Registration: IRCT2015042021874N1.

Keywords: breast cancer, CoQ10, quality of life, tamoxifen

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

More:
The Effect of CoQ10 Supplementation on Quality of Life in Women with B | PRBM - Dove Medical Press

Immunology

RAPT Therapeutics Announces Upcoming Investor Conference Presentations – Yahoo Finance

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (RAPT), a clinical-stage immunology-based biopharmaceutical companyfocused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that Brian Wong, M.D., Ph.D., its President and CEO, will be presenting at two upcoming conferences:

A live webcast and audio archive of both presentations may be accessed on the RAPT Therapeutics website athttps://investors.rapt.com/events-and-presentations. Please connect to the website 10 minutes prior to the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

AboutRAPT Therapeutics, Inc.RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively. The Company is also pursuing a range of targets, including general control nonderepressible 2 (GCN2) and hematopoietic progenitor kinase 1 (HPK1), that are in the discovery stage of development.

Media Contact:Angela Bittingmedia@rapt.com(925) 202-6211

Investor Contact:Sylvia Wheelerswheeler@wheelhouselsa.com

Read the original here:
RAPT Therapeutics Announces Upcoming Investor Conference Presentations - Yahoo Finance